X4 Pharmaceuticals (XFOR) Net Cash Flow (2017 - 2025)

X4 Pharmaceuticals has reported Net Cash Flow for 9 years, with the latest figure at $147.4 million in Q4 2025.

• For the quarter ending Q4 2025, Net Cash Flow rose 455.42% year-over-year to $147.4 million; the trailing twelve-month figure through Dec 2025 stood at $161.2 million (up 308.68% YoY), and the FY2025 full-year result was $161.2 million, up 469.54% from the prior year.
• Net Cash Flow for Q4 2025 stood at $147.4 million, up from $30.4 million in the prior quarter.
• The five-year high for Net Cash Flow was $147.4 million in Q4 2025, with the low at -$52.8 million in Q3 2023.
• Historically, Net Cash Flow has averaged $1.5 million across 5 years, with a median of -$15.4 million in 2022.
• Annual changes were most pronounced in 2022 — Net Cash Flow soared 654.31% — and 2023, when it plunged 261.51%.
• X4 Pharmaceuticals' Net Cash Flow stood at $5.5 million in 2021, then soared by 654.31% to $41.5 million in 2022, then slumped by 178.24% to -$32.5 million in 2023, then declined by 27.7% to -$41.5 million in 2024, then surged by 455.42% to $147.4 million in 2025.
• The last three Net Cash Flow figures came in at $147.4 million (Q4 2025), $30.4 million (Q3 2025), and -$1.2 million (Q2 2025), per Business Quant data.